NK
PharmaEssentia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BESREMi® (Ropeginterferon alfa-2b) | Polycythemia Vera | Commercial |
| Ropeginterferon alfa-2b | Essential Thrombocythemia | Phase 3 |
| P1101 (Ropeginterferon alfa-2b) | Various indications | Phase 1 |
| KX01 | Gastric, Gastro-esophageal, Esophageal Cancers | Phase 1 |
Leadership Team at PharmaEssentia
KL
Ko-Chung Lin
Founder and CEO
CT
Ching-Leou Teng
Chairperson
JH
Jack Hwang
General Manager, HQ
LL
Lih-Ling Lin
Chief Scientific Officer
AQ
Albert Qin
Chief Medical Officer
CC
ChaoSheng Cheng
Plant Director of Taichung Manufacturing Plant
SC
Snow Chang
Senior Director of Finance
KY
Katsuya Yonezu
Representative Director & General Manager of Japan Operations
TS
Toshiaki Sato
Executive Vice President, Head of R&D Division of Japan Global Clinical Study Director
WS
Warren Shen
General Manager of China Operations